19.09.2019 • NewsElaine BurridgeNouryon

Nouryon and Van Remmen Link on Water Treatment

Nouryon and Van Remmen Link on Water Treatment
Nouryon and Van Remmen Link on Water Treatment

Nouryon has partnered with Van Remmen UV Technology, a Dutch water treatment company, to develop a novel method to address the growing problem of pharmaceutical micropollutants in waste water.

Pharmaceuticals are designed not to be broken down by the body, meaning that they end up in wastewater treatment plants, which often cannot remove the often complex and persistent molecules.

Van Remmen said its Advanox advanced oxidation process in combination with Nouryon’s MicrOx hydrogen peroxide technology can offer a solution. Inside an Advanox reactor, UV light splits the hydrogen peroxide molecules into highly reactive hydroxyl radicals, which in turn break down the drugs.

“Growing global pharmaceutical use is creating a significant pollution problem for urban waste water treatment systems,” said Niek Stapel, managing director pulp and performance chemicals at Nouryon. “With this advanced water treatment concept, customers in the water treatment market will have access to two proven technologies that together enable measurement, monitoring and means to control micropollutants in waste water streams.”

The combined process is being tested in a sewage treatment plant in Växjö, Sweden, where a pilot plant was installed at the end of July. Pilot trials started on Aug. 6 for a month and the results will be compiled and sent to both the Swedish Environmental Research Institute and the Swedish Environmental Protection Agency where it will be compared to other technologies for advanced water treatment and pharmaceutical removal.

Nouryon, which is supplying the hydrogen peroxide for the project, said it expects the combined process to remove more than 90% of pharmaceutical residues.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.